初次椎体增强术后再次行椎体成形术或球囊后凸成形术的真实世界发生率及危险因素:一项回顾性队列研究
该回顾性队列研究利用商业保险理赔数据,纳入2008年1月1日至2020年6月30日期间因椎体压缩性骨折诊断后12个月内接受球囊后凸成形术(BKP)或椎体成形术(VP)的成人患者,分析24个月内再次接受BKP/VP治疗(作为后续症状性椎体骨折的替代指标)的发生率及预测因素。结果显示15.5%的患者接受了再次治疗,初始治疗节段数≥4、使用类固醇、Elixhauser合并症指数≥4及多发性骨髓瘤与风险增加相关,年龄<70岁与风险降低相关。
要点
- 15.5%的患者在初次椎体增强术后2年内接受了再次BKP/VP治疗。
- 初始治疗节段数≥4、类固醇使用、Elixhauser合并症指数≥4及多发性骨髓瘤与再次治疗风险增加相关。
- 年龄<70岁与再次治疗风险降低相关(AHR 0.81)。
核心结论
- 约七分之一的患者在初次椎体增强术后因椎体骨折接受了再次治疗。
- 基线患者特征与2年内再发骨折风险增加相关,提示患者的自然病史与再次治疗风险强烈相关,而非初始手术本身。
研究设计与样本
- 回顾性队列研究,使用商业保险理赔数据(Optum去标识化Clinformatics® Data Mart数据库)。
- 纳入2008年1月1日至2020年6月30日期间,因椎体压缩性骨折诊断后12个月内接受BKP或VP的成人患者共32,513例。
- 将初次BKP/VP后24个月内因椎体骨折接受再次治疗的患者分为「再次治疗」组或「无再次治疗」组,采用生存分析研究危险因素的影响。
主要发现
- 初始BKP/VP治疗节段数≥4与再次治疗风险增加相关(AHR 1.68,95%CI 1.24-2.26)。
- 类固醇使用与再次治疗风险增加相关(AHR 1.9,95%CI 1.31-1.48)。
- Elixhauser合并症指数≥4与再次治疗风险增加相关(AHR 1.44,95%CI 1.17-1.77)。
- 多发性骨髓瘤与再次治疗风险增加相关(AHR 1.31,95%CI 1.13-1.53);年龄<70岁与风险降低相关(AHR 0.81,95%CI 0.74-0.89)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The purpose of this study was to determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic vertebral fracture. Of patients, 15.5% underwent subsequent vertebral augmentation. The patient's comorbidities are strongly associated with risk of subsequent treatment. PURPOSE: To determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic and disabling vertebral fracture. METHODS: We conducted a retrospective cohort study using commercial insurance claims data (Optum's de-identified Clinformatics® Data Mart Database). Adult patients who underwent subsequent treatment for vertebral fracture within 24 months of initial balloon kyphoplasty (BKP) or vertebroplasty (VP) were classified into "subsequent treatment" or "no subsequent treatment" cohorts. Survival analysis was applied to investigate the effect of risk factors on subsequent treatment. RESULTS: Between 1 January 2008 and 30 June 2020, a total of 32,513 adult patients underwent a BKP/VP procedure following a diagnosis of vertebral compression fracture in the preceding 12 months. Five thousand thirty-five patients (15.5%) underwent a subsequent BKP/VP treatment within 2 years; 90% had a single fracture level treated. An increased hazard of subsequent treatment was associated with a number of fractures treated at initial BKP/VP (≥ 4 levels, adjusted hazard ratio (AHR) 1.68 (95% CI 1.24-2.26); steroid use, AHR 1.9 (95% CI 1.31-1.48); Elixhauser Comorbidity Index ≥ 4, AHR 1.44 (95% CI 1.17-1.77); and multiple myeloma, AHR 1.31 (95% CI 1.13-1.53)). Age < 70 years was associated with reduced hazard of subsequent treatment (AHR 0.81, 95% CI 0.74-0.89). CONCLUSIONS: One in seven patients underwent subsequent treatment for vertebral fracture after initial vertebral augmentation. Baseline patient characteristics were associated with increased risk of subsequent fracture within 2 years, suggesting that a patient's natural history is strongly associated with risk of subsequent treatment rather than the initial surgical procedure itself.
引用
- Hirsch JA, Gilligan C, Chandra RV, et al. Real-world rates and risk factors for subsequent treatment with vertebroplasty or balloon kyphoplasty after initial vertebral augmentation: a retrospective cohort study. Osteoporos Int. 2024. PMID: 39578267. doi:10.1007/s00198-024-07294-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。